呼吸系統領域的合作與授權協議（2016-2026）

呼吸系統領域合作的權威標桿

我們在呼吸系統領域的合作涵蓋了廣泛的急性和慢性疾病，其合約結構反映了生物製藥、吸入療法和標靶治療的持續創新，以及既定的治療模式。

本報告對呼吸系統領域的 455 項合作與許可協議進行了全面系統的分析，清楚地展示了整個市場夥伴關係的設計、談判和執行方式，並以證據為基礎進行了闡述。

充分了解市場標準。

本報告將幫助您準確了解呼吸系統領域交易的實際構成，並使您能夠：

• 自信地對標類似交易
• 對相關交易中的預付款、里程碑付款和特許權使用費結構進行詳細分析。
• 設定切合實際的市場參數
• 深入了解交易條款如何因開發階段、資產類型和合作夥伴情況而異。
• 支持實證評估和結構性決策
• 我們將根據實際交易數據進行內部討論，而不是根據假設。
• 了解主要企業如何處理交易
• 在不斷發展的治療領域，我們將合作夥伴的行為和重複的交易模式視覺化。
• 全面了解交易結構和執行情況
• 本報告超越了表面的交易數據，提供了對底層合約文件的訪問，使您能夠詳細了解實際合約是如何構建的。

這包括：

• 授予和保留的權利
• 負責開發和商業化
• 財務結構和支付觸發機制
• 關鍵合約條款和保障措施
• 這種程度的透明度對於了解呼吸系統疾病領域（尤其是慢性病領域，因為那裡已經存在既定的護理標準）的夥伴關係中如何分配價值、風險和控制至關重要。
• 它旨在為實際的業務發展和策略制定提供幫助。

本報告主要廣泛用於以下用途：

• 建構和基準化正在進行的交易
• 在清晰的市場環境下準備談判
• 合作機會及目的地評估
• 支援穩健且引人注目的數據驅動型內部策略
• 內容
• 呼吸領域共有 455 項合作與授權協議
• 財務條款，包括預付款、里程碑付款和版稅（如有揭露）。
• 可全文搜尋的合約目錄（依公司、治療領域及技術分類）
• 可直接查閱向美國證券交易委員會提交的合約和原始文件。
• 交易趨勢分析、關鍵交易和活躍負責人
• 關於呼吸系統領域交易的可靠、基於證據的參考資料。
• 本報告結合全面的交易報告和合約層面的深入分析，為如何在呼吸系統領域建立、談判和評估合作夥伴關係提供了可靠的、基於證據的參考資料。

目錄

摘要整理

第1章：引言

第2章：呼吸系統相關交易的趨勢

• 介紹
• 在呼吸領域長期夥伴關係
• 呼吸系統領域的合作關係（按交易類型分類）
• 呼吸系統領域的合作關係（按行業分類）
• 呼吸系統領域的合作（依研發階段分類）
• 呼吸領域合作（按技術類型分類）
• 呼吸系統領域的合作（依治療適應症分類）

第3章 呼吸夥伴關係的財務狀況

• 介紹
• 揭露呼吸系統相關夥伴關係的財務條款
• 呼吸夥伴關係的核心價值觀
• 呼吸系統相關合約- 預付款
• 呼吸系統相關合約的里程碑付款
• 呼吸系統相關專利費率

第4章 呼吸領域的主要交易與相關人員

• 介紹
• 在呼吸系統相關夥伴關係最活躍的公司
• 呼吸系統產業最活躍的交易公司名單
• 呼吸設備特價優惠（依價格排序）

第5章：呼吸系統合約文件清單

• 介紹
• 呼吸系統相關合作協議（如有）

第6章：呼吸系統治療標靶交易

• 介紹
• 呼吸治療標靶的交易
• 特價優惠列表
• 交易清單 - 與呼吸系統相關企業的交易（按公司分類）AZ
• 交易清單 - 按技術類型分類的呼吸系統相關交易
• 交易類型的定義
• 關於這家研究公司
• Current Partnering
• 目前合約
• 理想合作夥伴最新報告的標題

The definitive benchmark for respiratory dealmaking

Respiratory partnering spans a range of acute and chronic conditions, with deal structures reflecting established treatment paradigms alongside ongoing innovation in biologics, inhaled therapies, and targeted approaches.

This report provides a comprehensive and structured analysis of 455 respiratory collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how respiratory deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by stage, asset type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a mature yet evolving therapeutic landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within respiratory partnerships, particularly across chronic disease settings with established standards of care.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark live transactions
• Prepare for negotiations with well-defined market context
• Evaluate partnership opportunities and counterparties
• Support internal strategy with robust, defensible data
• What's included
• 455 respiratory collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy, and technology)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for respiratory dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how respiratory partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in respiratory dealmaking

• 2.1. Introduction
• 2.2. Respiratory partnering over the years
• 2.3. Respiratory partnering by deal type
• 2.4. Respiratory partnering by industry sector
• 2.5. Respiratory partnering by stage of development
• 2.6. Respiratory partnering by technology type
• 2.7. Respiratory partnering by therapeutic indication

Chapter 3 - Financial deal terms for respiratory partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for respiratory partnering
• 3.3. Respiratory partnering headline values
• 3.4. Respiratory deal upfront payments
• 3.5. Respiratory deal milestone payments
• 3.6. Respiratory royalty rates

Chapter 4 - Leading respiratory deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in respiratory partnering
• 4.3. List of most active dealmakers in respiratory
• 4.4. Top respiratory deals by value

Chapter 5 - Respiratory contract document directory

• 5.1. Introduction
• 5.2. Respiratory partnering deals where contract document available

Chapter 6 - Respiratory dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by respiratory therapeutic target
• Deal directory
• Deal directory - Respiratory deals by company A-Z
• Deal directory - Respiratory deals by technology type
• Deal type definitions
• About Bioharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Respiratory partnering since 2016
• Figure 2: Respiratory partnering by deal type since 2016
• Figure 3: Respiratory partnering by industry sector since 2016
• Figure 4: Respiratory partnering by stage of development since 2016
• Figure 5: Respiratory partnering by technology type since 2016
• Figure 6: Respiratory partnering by indication since 2016
• Figure 7: Respiratory deals with a headline value
• Figure 8: Respiratory deals with upfront payment values
• Figure 9: Respiratory deals with milestone payment
• Figure 10: Respiratory deals with royalty rates
• Figure 11: Active respiratory dealmaking activity since 2016
• Figure 12: Top respiratory deals by value since 2016